Henry Wheeler

About Henry Wheeler

Henry Wheeler is a senior executive with expertise in investor relations, corporate communications and financial markets within the pharmaceutical and biopharmaceutical sectors. He currently serves as Vice President, Investor Relations and Communications at Innate Pharma, a Paris-listed biotech company also listed on Nasdaq. He joined Innate Pharma in June 2021 and was appointed to the executive committee in January 2023, reflecting the strategic importance of his role in shaping the company’s dialogue with investors, analysts and other stakeholders. Before joining Innate Pharma, Wheeler worked at AstraZeneca, where he led investor relations for the company’s oncology portfolio after previously serving within the Oncology Business Unit. That experience gave him deep exposure to oncology drug development, clinical-stage communication and the expectations of global capital markets in a highly regulated environment. He also held healthcare-focused financial and research roles at Third Bridge and Morgan Stanley in London, building a strong foundation in equity markets, sector analysis and investor engagement. Wheeler graduated from King’s College London with an MSc in Drug Discovery Skills and a BSc with honours in Pharmacology. His profile combines scientific literacy with significant experience in capital markets and shareholder communication, making him well suited to support a clinical-stage biotech company. At Innate Pharma, he plays a key role in communicating the company’s strategy, pipeline progress and value proposition, particularly around its ANKET® platform and broader growth agenda. In a biotech setting where market confidence and narrative clarity are essential, his responsibilities are central to the company’s external positioning and investor credibility.